Salarius Pharmaceuticals, Inc. (DCOY)
NASDAQ · Healthcare
Salarius Pharmaceuticals, Inc. EBITDA 2015–2022
Salarius Pharmaceuticals, Inc. annual/quarterly ebitda history and growth rate from 2018 to 2023. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Salarius Pharmaceuticals, Inc. ebitda for the quarter ending March 31, 2023 was -5.4 M, a 11.34% decrease year-over-year.
- Salarius Pharmaceuticals, Inc. ebitda for the twelve months ending March 31, 2023 was -15.7 M.
- Salarius Pharmaceuticals, Inc. annual ebitda for 2022 was -31.8 M, a 148.83% increase from 2021.
- Salarius Pharmaceuticals, Inc. annual ebitda for 2021 was -12.8 M, a 64.69% increase from 2020.
- Salarius Pharmaceuticals, Inc. annual ebitda for 2020 was -7.8 M, a 4.54% decrease from 2019.
- Salarius Pharmaceuticals, Inc. annual ebitda for 2019 was -8.1 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Salarius Pharmaceuticals, Inc. EBITDA — FAQ
Salarius Pharmaceuticals, Inc. (DCOY) ebitda over the last 8 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see DCOY's ebitda history?
The chart and table above show Salarius Pharmaceuticals, Inc.'s ebitda by year and by quarter, including the growth rate.